Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives $17.00 Consensus PT from Brokerages

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) has received an average rating of “Buy” from the nine research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and two have issued a strong buy rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $17.00.

IVA has been the subject of a number of recent analyst reports. Barclays assumed coverage on shares of Inventiva in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $18.00 price objective for the company. UBS Group initiated coverage on shares of Inventiva in a research report on Wednesday, January 7th. They issued a “buy” rating and a $12.00 target price for the company. Leerink Partners assumed coverage on shares of Inventiva in a research note on Monday, January 12th. They set an “outperform” rating and a $12.00 target price for the company. HC Wainwright set a $24.00 price target on shares of Inventiva and gave the company a “buy” rating in a report on Wednesday, January 28th. Finally, Guggenheim dropped their price target on shares of Inventiva from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Creative Planning bought a new position in Inventiva during the second quarter valued at approximately $32,000. Virtu Financial LLC bought a new stake in Inventiva in the fourth quarter worth approximately $60,000. XTX Topco Ltd acquired a new position in shares of Inventiva during the 4th quarter worth $84,000. Cerity Partners LLC bought a new position in shares of Inventiva during the 4th quarter valued at $93,000. Finally, NewEdge Advisors LLC bought a new position in shares of Inventiva during the 3rd quarter valued at $116,000. 19.06% of the stock is owned by institutional investors and hedge funds.

Inventiva Price Performance

Inventiva stock opened at $6.16 on Friday. Inventiva has a fifty-two week low of $2.70 and a fifty-two week high of $7.98. The firm’s 50 day simple moving average is $6.24 and its 200-day simple moving average is $5.36.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.